IL37 and psoriasis: For patients requiring systemic therapies, biological medications such as TNF-alpha inhibitors (Adalimumab, Etanercept, Infliximab), IL-12/IL-23 inhibitors (Ustekinumab), and IL-17 inhibitors (Secukinumab and Ixekizumab) are available for psoriasis treatment.